Results 11 to 20 of about 529,540 (301)

Anti-vascular endothelial growth factor treatment for eye diseases [PDF]

BMJ, 2012
Treatment is clearly effective but important clinical and public health implications ...
Wong, TY, Cheung, N, Lam, DSC
openaire   +6 more sources

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy [PDF]

Cochrane Database of Systematic Reviews, 2014
Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of
Martínez Zapata, Mª José, Martí Carvajal, Arturo José, Solà, Ivan, Pijoán, José I., Buil Calvo, José Antonio, Cordero Rigol, José Antonio, Evans, Jennifer R.   +6 more
openaire   +8 more sources

Anti-vascular endothelial growth factor for diabetic macular oedema [PDF]

, 2014
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk of visual loss in DMO, or clinically significant macular oedema (CSMO), vision is rarely improved.
VIRGILI, GIANNI, Parravano M, Menchini F, Brunetti M.   +3 more
openaire   +5 more sources

Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer [PDF]

Molecular Cancer, 2003
As with other solid tumors, the growth and metastasis of pancreatic cancer is critically dependent on tumor angiogenesis. A major stimulus for a tumor's recruitment of additional blood vessels is cellular hypoxia, a condition which is especially ...
Reber Howard A, Eibl Guido, Duffy John P, Hines Oscar J   +3 more
doaj   +4 more sources

ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY

Retina, 2022
Background/Purpose: Anti–vascular endothelial growth factor therapies have proven effective in treating retinal diseases but come with a high financial burden to the patient and health care system. Biosimilar drugs present an opportunity to decrease the cost of these important ophthalmic medications, and several ophthalmic ...
Kaiser, Peter K., Schmitz-Valckenberg, Marc Steffen, Holz, Frank G.   +2 more
openaire   +2 more sources

In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis [PDF]

, 2014
Methodology: We have utilized a rational in silico-based approach to demonstrate the design and study of a novel compound that acts as a dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1).
AM Latham, Antony M. Latham, B Apsel, Colin W. G. Fishwick, D Santamaria, Domenico Ribatti, E Schonbrunn, EA Murphy, G Bergers, G Draetta, Gareth W. Fearnley, GI Evan, GJ Howell, GW Fearnley, H Haddad, H Huynh, I Zachary, J Galon, J Kankanala, J Lee, J Pines, Jayakanth Kankanala, JC Tille, JJ Tung, JM Ebos, JW Schmidberger, K Boda, KM Malinda, M Doree, M Mohammadi, MA Ali, MA Branca, Mark T. Kearney, Matthew C. Gage, MP Jacobson, MS Squires, N Ferrara, O Timofeev, P Carmeliet, P Carmeliet, PA Harris, PG Wyatt, Q Wang, R Morphy, RA Friesner, RA Friesner, S Emanuel, S Huang, S Koch, S Koch, S Ponnambalam, Shervanthi Homer-Vanniasinkam, Sreenivasan Ponnambalam, Stephen B. Wheatcroft, T Anastassiadis, T Bashir, TA Halgren, TA Potapova, V Knights, VE Neubrand, ZW Cai   +60 more
core   +10 more sources

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

Cochrane Database of Systematic Reviews, 2023
Proliferative diabetic retinopathy (PDR) is an advanced complication of diabetic retinopathy that can cause blindness. It consists of the presence of new vessels in the retina and vitreous haemorrhage. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision.
Martinez-Zapata M. J., Salvador I., Marti-Carvajal A. J., Pijoan J. I., Cordero J. A., Ponomarev D., Kernohan A., Sola I., Virgili G.   +8 more
openaire   +5 more sources

Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report

Journal of Medical Case Reports, 2021
Background Intravitreal injections of anti-vascular endothelial growth factor are commonly used to treat macular diseases, including diabetic macular edema.
Miwako Yoshimoto, Nobuhiko Takeda, Takayuki Yoshimoto, Shun Matsumoto   +3 more
doaj   +1 more source

Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma [PDF]

Journal of Clinical Oncology, 2015
Treatment of glioblastoma (GBM), the most common primary malignant brain tumor in adults, remains a significant unmet need in oncology. Historically, cytotoxic treatments provided little durable benefit, and tumors recurred within several months.
Lu-Emerson, Christine, Duda, Dan G, Emblem, Kyrre E, Taylor, Jennie W, Gerstner, Elizabeth R, Loeffler, Jay S, Batchelor, Tracy T, Jain, Rakesh K   +7 more
openaire   +4 more sources

Debate on the various anti-vascular endothelial growth factor drugs

Indian Journal of Ophthalmology, 2008
Khalili Mohammad, Hosseini Hamid
doaj   +3 more sources